Werewolf Reports No Revenue in Fiscal Q2
Werewolf Therapeutics (NASDAQ:HOWL), an early-stage biotechnology company dedicated to innovative cancer immunotherapies, reported its second quarter 2025 results on August 14, 2025. The main story this period: it continues to invest heavily in research while awaiting critical clinical milestones, with GAAP EPS loss was $0.40 and no revenue, mirroring consensus forecasts. While commercial activity was muted, Research and development and general and administrative expenses declined compared to the same period in 2024, along with setting the tone for the remainder of fiscal 2025. Net loss (GAAP) was $18.0 million, compared to $17.2 million for the same period in 2024. The quarter showed stable execution, but all eyes are on late 2025 clinical and regulatory events.
Source: Analyst estimates for the quarter provided by FactSet.
Werewolf Therapeutics is a biopharmaceutical company specializing in cancer immunotherapy. It is focused on creating conditionally activated biology, using a proprietary PREDATOR platform to craft treatments that target tumors while sparing healthy tissue. The company is primarily engaged in the development of next-generation cytokine therapies and T-cell engaging drugs designed for improved safety and effectiveness.
Source Fool.com
